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Globally, lung cancer is the leading cause of cancer-related
mortality in both men and women (Ferlay et al, 2000), with non-
small-cell lung cancer (NSCLC) accounting for 80% of these cases.
Many patients present with advanced/metastatic disease. Despite
aggressive surgical or chemotherapeutic intervention, the prog-
nosis of patients diagnosed with NSCLC remains poor, with an
overall cure rate of o15% (Sridhar et al, 2003). Therefore, new
safe and effective treatments for NSCLC are urgently needed.
Aberrant cell signalling by receptor tyrosine kinases such as the
epidermal growth factor receptor (EGFR) is known to play a
critical role in the development and progression of cancer (Ullrich
et al, 1984; Zwick et al, 2001). The EGFR pathway is highly
expressed in a variety of solid tumours, including NSCLC, and has
been implicated in tumorigenesis through its effects upon cell-
cycle progression, apoptosis, angiogenesis, tumour-cell motility
and metastasis (Ciardiello and Tortora, 2001; Salomon and Gullick,
2001; Arteaga, 2002; Bunn Jr and Franklin, 2002). As EGFR
expression correlates with poor prognosis, disease progression and
resistance to chemotherapy (Baselga, 2002; Wells, 2000), it has
been identified as a potential therapeutic target in the treatment of
cancer.
Gefitinib (‘Iressa’, ZD1839) is the first of a new class of EGFR
tyrosine kinase inhibitors and, as such, physicians and patients are
taking a great interest in its clinical profile and development.
Two Phase II monotherapy trials (‘Iressa’ Dose Evaluation in
Advanced Lung cancer (IDEAL) 1 and 2) have reported
unprecedented antitumour activity and symptom relief in pre-
treated patients with advanced/metastatic NSCLC (Fukuoka et al,
2003); approximately 40% of patients experienced objective
responses and stable disease accompanied by improvement in
disease-related symptoms and 30% of patients survived for 1 year.
The IDEAL trials underpinned the current use of gefitinib in
clinical practice and, as of September 2003, gefitinib had been
administered to approximately 90000 patients worldwide. The
only FDA-approved option for use in patients with NSCLC that has
failed both platinum-based and docetaxel chemotherapy in the
USA, gefitinib is also approved for use in previously treated
patients in several other countries, including Japan and Australia.
Our thirst for new knowledge of how best to use this novel targeted
agent remains unquenched, and data from the real-life use of
gefitinib can provide invaluable insight into the clinical application
of gefitinib in a wide variety of settings.
The ‘Iressa’ Expanded Access Programme (EAP) enables
patients to receive 250mgday
1 gefitinib if they are ineligible for
clinical trials or have no other treatment options available. To date
(September 2003), approximately 40000 generally heavily pre-
treated patients with advanced NSCLC, in 73 countries, have
received gefitinib on a compassionate-use basis via the EAP. Thus,
the EAP provides a wealth of real-life experience of using gefitinib
in elderly patients, patients with poor performance status and
those with brain metastases. It is important that the experience of
using gefitinib in the EAP is shared between all physicians who are
striving to provide the best level of care for their patients,
including those who are not necessarily part of the EAP.
In June 2003, the ‘Iressa’ Clinical Experience (ICE) meeting was
held in Madrid, Spain, and provided a unique opportunity for 150
EAP investigators to disseminate the real-life experience of
gefitinib generated through EAP usage. The sharing of case reports
and series by EAP physicians generated an overall (rather than
individual) perception of the efficacy, safety and quality-of-life
impact of gefitinib. Unique insights into the clinical use of gefitinib
were gained from the meeting, some of them unexpected. In order
to disseminate this knowledge to all physicians, the data presented
at the ICE meeting have been used to describe the concept of
assessing clinical benefit, the tolerability, the treatment of patients
with brain metastases and the treatment of elderly and unfit
patients, using gefitinib in a real-life setting. These data will
provide physicians with invaluable insight into the clinical
application of gefitinib in a wide variety of settings, and enable
them to provide the best level of care for their patients.
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